Please login to the form below

Not currently logged in
Email:
Password:

Fostair

This page shows the latest Fostair news and features for those working in and with pharma, biotech and healthcare.

Chiesi targets patient adherence via mobile app

Chiesi targets patient adherence via mobile app

The app, which will be used by healthcare professionals, is specifically catered to those who have been prescribed Chiesi’s Fostair (beclometasone/formoterol) pressurised metered-dose inhaler (pMDI) or dry powder ... Tom Delahoyde, managing director of

Latest news

  • PMCPA 'appalled' by Chiesi's Code of Practice breach PMCPA 'appalled' by Chiesi's Code of Practice breach

    The firm has been reprimanded by the PMCPA, which polices the UK's self-regulatory code, for making a “misleading and unsubstantiated claim” about its asthma drug Fostair (beclometasone/formoterol). ... But over and above this, the PMCPA said there

  • Wit and Visual Intrigue Wit and Visual Intrigue

    In the melee and rush of social media, how are print ads faring? Not especially well, suggests Reg Manser, who finds three made him look twice. - PMLiVE

  • Breathing easier

    formoterol (Fostair/Foster/Inuvair, Chiesi Farmaceutici) — this article will focus specifically on the ß2-adrenoceptor agonist and bronchodilator indacaterol.  .

  • Bitter sweet

    Kelly Underwood-Fone, co-founder and director of Lime Advertising, looks at how too much client interference can sour good creative concepts

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics